The U.S. Food and Drug Administration (FDA) has approved Pfizer’s HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors.   HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) app...